Video

Dr. Leonard Gomella on unanswered questions with biomarkers in prostate cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Leonard G. Gomella, MD, chairman of the Department of Urology at the Sidney Kimmel Cancer Center, discusses questions that still need to be resolved with biomarkers for the diagnosis and management of patients with prostate cancer.

      Related Videos
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
      De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      1 expert in this video
      Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
      1 expert in this video
      Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      1 expert in this video
      Comparing Trials Studying Treatment Intensification In mHSPC
      An Overview of the ARANOTE Trial
      An Overview of the ARANOTE Trial
      Related Content
      FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
      May 21st 2025

      FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

      Hannah Clarke
      The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
      May 20th 2025

      Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

      Hannah Clarke
      The phase 3 study design will now be submitted for final review by the agency.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      SBRT may offer a safe alternative to CFRT after prostatectomy
      May 16th 2025

      SBRT may offer a safe alternative to CFRT after prostatectomy

      Hannah Clarke
      Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      © 2025 MJH Life Sciences

      All rights reserved.